GPT Healthcare Limited Financial Results and Annual Report Disclosure

Reporting Period: FY 2025-26

Financial Performance Overview

GPT Healthcare reported mixed financial results for FY26 with revenue growth but profit decline:

  • Revenue from Operations: ₹478.50 crore (₹47,254.70 lakh), up 15.1% from FY25 (₹415.59 crore)
  • PAT: ₹42.22 crore (₹4,222.05 lakh), down 15.4% from FY25 (₹49.92 crore)
  • EPS: ₹5.15 (Basic and Diluted) vs ₹6.08 in FY25
  • EBITDA: ₹90.13 crore, down 1.9% from FY25 (₹91.85 crore)

The decline in profitability was primarily due to ramp-up costs associated with the newly commissioned ILS Raipur hospital, which reported an EBITDA loss of ₹13.8 crore during the year.

Operational Highlights and Expansion

Hospital Network Expansion:

  • Commissioned ILS Raipur in May 2025 with 158 beds (asset-light rental model)
  • Signed MOU for Jamshedpur hospital (155-bed facility) with project outlay of ₹75 crore, expected commissioning Q4 FY27
  • Total operating capacity: 719 beds across 5 hospitals
  • Targeting 1,000+ bed network within two years with evaluations in Uttar Pradesh, Assam, and Odisha

Clinical Capabilities:

  • 800+ robotic surgeries performed at Salt Lake facility
  • Orthopaedic robot commissioned at Howrah
  • Comprehensive cancer care with PET scan and Linear Accelerator at Agartala
  • CTVS unit commissioned at Dum Dum
  • Liver transplant licence received at Raipur

Operational Metrics:

  • ARPOB: ₹39,243, up 5.5% from ₹37,180 in FY25
  • Bed Occupancy: 45.9% vs 53.1% in FY25 (impacted by Raipur ramp-up)
  • Full-time consultants: 115; Visiting consultants: 630

Financial Position and Ratios

Capital Structure:

  • Equity Share Capital: ₹82.05 crore (8,20,54,823 shares of ₹10 each)
  • Net Debt-free balance sheet maintained
  • D/E ratio: 0.34x (increased from 0.14x due to Raipur financing)
  • CRISIL Rating: A-/Stable (Long Term), A2+ (Short Term) reaffirmed

Key Financial Ratios:

  • Current ratio: 1.12 (1.06 in FY25)
  • Return on equity: 16.32% (21.41% in FY25)
  • Net profit ratio: 8.93% (12.26% in FY25)
  • Debt service coverage ratio: 4.77 (10.03 in FY25)

Lease Commitments and Financing

The company has significant lease arrangements:

  • Right-of-use assets: ₹7,631.30 lakhs (increased from ₹2,433.48 lakhs)
  • Lease liabilities: ₹7,507.02 lakhs
  • Additions during year: ₹6,630.06 lakhs for new facilities
  • Finance costs increased to ₹824.04 lakhs from ₹347.15 lakhs YoY

Dividend and Corporate Actions

Dividend Declaration:

  • Interim dividend of ₹1.00 declared November 8, 2025
  • Final dividend of ₹1.50 recommended May 18, 2026 (subject to shareholder approval)
  • Total dividend for FY26: ₹2.50 per share (25%)
  • Record date: Thursday, July 30, 2026
  • Total dividend payout: ₹2,051.37 lakh for FY26

37th Annual General Meeting

Date: Thursday, August 6, 2026 at 3:00 PM IST

Mode: Video Conferencing

Key Agenda Items:

  • Adoption of audited financial statements for FY 2025-26
  • Declaration of final dividend
  • Re-appointment of directors including Dr. Aruna Tantia, Mr. Hari Modi, and Dr. Tapti Sen
  • Approval of related party transactions and remuneration increases

Contingent Liabilities and Commitments

Contingent Liabilities:

  • Income tax matter: ₹494.24 lakhs under dispute (assessment orders disallowing expenses under Section 37(1))
  • Bank guarantees outstanding: ₹76.53 lakhs
  • Management believes company has strong grounds and expects favorable outcome

Capital Commitments: ₹699.14 lakhs remaining to be executed

Corporate Governance and Compliance

Board Changes:

  • Late Dwarika Prasad Tantia (Executive Chairman) passed away on August 17, 2025
  • Dr. Om Tantia elevated to Chairman and Managing Director effective November 8, 2025
  • Mr. Shree Gopal Tantia appointed as Vice Chairman effective November 8, 2025

Regulatory Compliance:

  • Filed under Regulation 30 of SEBI Listing Regulations
  • All statutory compliances met including CSR expenditure of ₹128.69 lakhs
  • No qualifications from statutory, secretarial, or cost auditors

Forward-looking Guidance

  • FY27 Revenue Growth guidance: ~15% YoY
  • FY27 EBITDA Margin guidance: ~20.2%
  • ARPOB Growth guidance: ~8%
  • Raipur expected to reach monthly EBITDA breakeven within 6-8 months (target Q3 FY27)
  • Long-term ROE/ROCE target: ~25%